Sothema published its third-quarter indicators on 17 November 2026.
Consolidated revenue for the quarter reached MAD 940 million, compared with MAD 757 million a year earlier (+24%). Over the first nine months, it came to MAD 2,736 million, against MAD 2,306 million (+19%). According to the release, growth came from chronic disease treatments and ophthalmology, as well as the subsidiaries Axess Pharma (oncology) and Soludia (dialysis).
Capital expenditure reached MAD 130 million at end-September, compared with MAD 49 million a year earlier, notably for the acquisition of a brand’s rights in Morocco. Consolidated net debt fell 9% compared with end-2025.
Source: Sothema, communiqué financier T3 2026 (via Médias24), November 17, 2026.